NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA’s 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company’s broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers.
The completion of the oral gummy formulation marks a significant milestone for NanoViricides, as it enables a patient-friendly dosing method for the antiviral drug candidate. NV-387 is a unique broad-spectrum antiviral that has shown efficacy in animal models for monkeypox, smallpox, measles, and other respiratory viral infections including RSV, COVID-19, and influenza. The drug successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, paving the way for the upcoming Phase II trial.
The company’s presentation at the NIBA conference is expected to provide investors and industry stakeholders with detailed insights into the development timeline and strategic direction. Diwan will discuss the company’s nanomaterial-based antiviral platform, which aims to address unmet medical needs in viral diseases with limited treatment options. The conference provides a platform for NanoViricides to highlight its progress and engage with potential partners and investors.
NanoViricides is a clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. In addition to NV-387, the company is developing NV-HHV-1 for the treatment of herpesvirus infections, including HSV-1, HSV-2, VZV shingles, and chickenpox. The company cannot project an exact date for filing an IND for any of its drugs due to dependence on external collaborators and consultants.
For more information on the latest news and updates relating to NNVC, visit the company’s newsroom at https://ibn.fm/NNVC.
The announcement underscores NanoViricides’ commitment to advancing its antiviral pipeline, with NV-387 positioned as a potential treatment for multiple viral threats. The move to an oral gummy formulation could enhance patient compliance and accessibility, particularly in resource-limited settings where the monkeypox outbreak has been most severe. The upcoming Phase II trial in the Democratic Republic of Congo will be a critical step in demonstrating the drug’s efficacy in affected populations.
Investors and healthcare professionals will be watching closely as NanoViricides presents its data and future plans at the NIBA conference. The company’s progress reflects broader efforts in the biotech sector to develop broad-spectrum antivirals that can respond to emerging viral diseases.
